Preclinical research identified palbociclib as an unexpected suppressor of β-catenin signaling that synergizes with KRAS or ERK5 inhibition in colorectal cancer models. (Journal of Translational Medicine)
CDK4/6 inhibitor palbociclib targets β-catenin in KRAS-mutant tumors
The CRC Digest